Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse

Atherosclerosis

Volumn 202, Issue 1, 2009, Pages 84-91

  McClelland, Sarah ^a   Gawaz, Meinrad ^b   Kennerknecht, Elisabeth ^c   Konrad, Carolin Sophie Ildiko ^c   Sauer, Susanne ^c   Schuerzinger, Katrin ^c   Massberg, Steffen ^c,d   Fitzgerald, Desmond J ^a   Belton, Orina ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Atherosclerosis; COX 1 gene deletion; Platelets; Thromboxane

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; CYCLOOXYGENASE 1; THROMBOXANE A2; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; FEMALE; GENE DELETION; KNOCKOUT GENE; MALE; MOUSE; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; PROSTAGLANDIN URINE LEVEL; THROMBOCYTE; THROMBOCYTE ADHESION;

ANIMALS; AORTA, THORACIC; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PLATELETS; CYCLOOXYGENASE 1; ENDOTHELIUM, VASCULAR; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; THROMBOXANE A2; THROMBOXANE B2;

EID: 57649148913     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.04.016     Document Type: Article

References (37)

1. Belton O.A., Duffy A., Toomey S., and Fitzgerald D.J. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 108 24 (2003) 3017-3023
2. Pratico D., Cyrus T., Li H., and Fitzgerald G.A. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 96 12 (2000) 3823-3826
3. FitzGerald G.A., Smith B., Pedersen A.K., and Brash A.R. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 310 17 (1984) 1065-1068
4. Belton O., Byrne D., Kearney D., Leahy A., and Fitzgerald D.J. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102 8 (2000) 840-845
5. Zidar N., Dolenc-Strazar Z., Jeruc J., et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the normal human heart and in myocardial infarction. Cardiovasc Pathol 16 5 (2007) 300-304
6. Schonbeck U., Sukhova G.K., Graber P., Coulter S., and Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155 4 (1999) 1281-1291
7. Wong E., Huang J.Q., Tagari P., and Riendeau D. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis 157 2 (2001) 393-402
8. Pratico D., Tillmann C., Zhang Z.B., Li H., and FitzGerald G.A. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 98 6 (2001) 3358-3363
9. Connolly E., Bouchier-Hayes D.J., Kaye E., Leahy A., Fitzgerald D., and Belton O. Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty. J Pharmacol Exp Ther 300 2 (2002) 393-398
10. Babaev V.R., Ding L., Reese J., et al. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice. Circulation 113 1 (2006) 108-117
11. Theilmeier G., Michiels C., Spaepen E., et al. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood 99 12 (2002) 4486-4493
12. Massberg S., Brand K., Gruner S., et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 196 7 (2002) 887-896
13. Coppinger J.A., Cagney G., Toomey S., et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 103 6 (2004) 2096-2104
14. Clarke R.J., Mayo G., Price P., and Fitzgerald G.A. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 325 16 (1991) 1137-1141
15. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 25 (2001) 1809-1817
16. Cyrus T., Sung S., Zhao L., Funk C.D., Tang S., and Pratico D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 106 10 (2002) 1282-1287
17. Egan K.M., Wang M., Fries S., et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111 3 (2005) 334-342
18. Cayatte A.J., Du Y., Oliver-Krasinski J., Lavielle G., Verbeuren T.J., and Cohen R.A. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 20 7 (2000) 1724-1728
19. Kobayashi T., Tahara Y., Matsumoto M., et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 114 6 (2004) 784-794
20. Ho E., Rooney C., Harhen B., et al. Atherosclerosis and oxidative stress contribute to aspirin nonresponse in hypertensive subjects. Circulation 110 17 (2004) 608-608, Suppl. Abstract
21. Pulcinelli F.M., Riondino S., Celestini A., et al. Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J Thromb Haemost 3 12 (2005) 2784-2789
22. Janssen A., Maier T.J., Schiffmann S., et al. Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. Eur J Pharmacol 540 1-3 (2006) 24-33
23. Loftin C.D., Trivedi D.B., Tiano H.F., et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc Natl Acad Sci USA 98 3 (2001) 1059-1064
24. Tangirala R.K., Rubin E.M., and Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 36 (1995) 2320-2328
25. Toomey S., Harhen B., Roche H.M., Fitzgerald D.J., and Belton O. Profound resolution of early atherosclerosis with conjugated linoleic acid. Atherosclerosis 187 1 (2006) 40-49
26. Massberg S., Gawaz M., Gruner S., et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 197 1 (2003) 41-49
27. Catella F., and FitzGerald G.A. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res 47 6 (1987) 647-656
28. Gresele P., Catalano M., Giammarresi C., et al. Platelet activation markers in patients with peripheral arterial disease-a prospective comparison of different platelet function tests. Thromb Haemost 78 6 (1997) 1434-1437
29. Burleigh M.E., Babaev V.R., Patel M.B., et al. Inhibition of cyclooxygenase with indomethicin phenethylamide reduces atherosclerosis in apoE-null mice. Biochem Pharmacol 70 3 (2005) 334-342
30. Janssen A., Maier T.J., Schiffman S., et al. Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. Eur J Pharmacol 540 1-3 (2006) 24-33
31. Gawaz M., Langer H., and May A.E. Platelets in inflammation and atherogenesis. J Clin Invest 115 12 (2005) 3378-3384
32. Massberg S., Schurzinger K., Lorenz M., et al. Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb. Circulation 112 8 (2005) 1180-1188
33. Methia N., Andre P., Denis C.V., Economopoulos M., and Wagner D.D. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood 98 5 (2001) 1424-1428
34. Gawaz M. Platelets in the onset of atherosclerosis. Blood Cells Mol Dis 36 2 (2006) 206-210
35. Gruner S., Prostredna M., Schulte V., et al. Multiple integrin-ligand interactions synergize in shear-resistant platelet adhesion at sites of arterial injury in vivo. Blood 102 12 (2003) 4021-4027
36. Capone M.L., Sciulli M.G., Tacconelli S., et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45 8 (2005) 1295-1301
37. Zhuge X., Arai H., Xu Y., et al. Protection of atherogenesis in thromboxane A2 receptor-deficient mice is not associated with thromboxane A2 receptor in bone marrow-derived cells. Biochem Biophys Res Commun 351 4 (2006) 865-871